Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
Karyopharm Therapeutics Inc
Cancer Research UK
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Senti Biosciences
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
Cancer Research UK
Case Comprehensive Cancer Center
University of Iowa
Thomas Jefferson University
Thomas Jefferson University
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation
Incyte Corporation
University of Rochester
Mayo Clinic
Affiliated Hospital of Qinghai University
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Asan Medical Center
University of Nebraska
Northwestern University
Barbara Ann Karmanos Cancer Institute
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
Fred Hutchinson Cancer Center
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
JaxBio Ltd
Karyopharm Therapeutics Inc
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Ohio State University Comprehensive Cancer Center
University Hospital, Antwerp
Advice Pharma Group srl
Alliance for Clinical Trials in Oncology
Roswell Park Cancer Institute
Newave Pharmaceutical Inc